EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
Alessia Alunno, Aurélie Najm, Pedro Machado, Heidi Bertheussen, Gerd R Burmester, Francesco Carubbi, Gabriele De Marco, Roberto Giacomelli, Olivier Hermine, John D. Isaacs, Isabelle Koné‐Paut, César Magro‐Checa, Iain B. McInnes, Pier Luigi Meroni, Luca Quartuccio, Athimalaipet V Ramanan, Manuel Ramos‐Casals, Javier Rodríguez‐Carrio, Hendrik Schulze‐Koops, Tanja Stamm, Sander W. Tas, Benjamin Terrier, Dennis McGonagle, Xavier Mariette
Topics & Concepts
MedicineTocilizumabPathophysiologyIntensive care medicineCoronavirus disease 2019 (COVID-19)Immune dysregulationDiseaseImmunologyRheumatologyClinical trialImmune systemBioinformaticsInternal medicineInfectious disease (medical specialty)BiologyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19